Hikma to Launch Colchicine 0.6mg Capsules

Zeitungsständer (Symbolbild). © Global_Pics / iStock Unreleased / Getty Images

PR Newswire

LONDON, January 9, 2015

LONDON, January 9, 2015 /PRNewswire/ --

Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today notes that Takeda Pharmaceuticals U.S.A. Inc. ("Takeda") has been unsuccessful in appealing the decision by the United States District Court for the District of Delaware to deny Takeda's motion for a preliminary injunction in relation to the distribution of Hikma's colchicine 0.6mg capsules for the prophylaxis of gout flares in adults. The injunction, which was granted to Takeda on 9 October 2014, has been vacated.

Hikma will now prepare to distribute its colchicine, which it will market under the brand name MITIGARE™. Hikma will also be preparing to launch an authorised generic of MITIGARE™, increasing patient access to this important product.

Said Darwazah, Chairman and CEO of Hikma, said:

"I am very pleased to be launching our colchicine products, demonstrating our success in developing a more differentiated product portfolio for the US market."

According to IMS Health, sales of colchicine in the US market were approximately $688 million for the 12 months ending August 2014.

About Hikma

ARIVA.DE Börsen-Geflüster

Kurse

Hikma Pharmaceuticals

21,00 €

-1,87%

HIKMA PHARMS PLC S/ADR

48,91 $

0,00%

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Branded", "Injectables" and "Generics", based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Enquiries

Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations  +44(0)20-7399-2760
Lucinda Henderson, Deputy Director of Investor Relations                 +44(0)20-7399-2765

FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44(0)20-3727-1000

Mehr Nachrichten zur Hikma Pharmaceuticals Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.